메뉴 건너뛰기




Volumn 28, Issue 16, 2010, Pages 2705-2711

Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GOSERELIN; LETROZOLE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE;

EID: 77954934986     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.5884     Document Type: Article
Times cited : (45)

References (28)
  • 2
    • 37449028688 scopus 로고    scopus 로고
    • Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-Month analysis of the ATAC trial
    • Forbes JF, Cuzick J, Buzdar A, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-Month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
    • (2008) Lancet Oncol , vol.9 , pp. 45-53
    • Forbes, J.F.1    Cuzick, J.2    Buzdar, A.3
  • 3
    • 17444453765 scopus 로고    scopus 로고
    • Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
    • DOI 10.1016/S0959-8049(03)00602-6
    • Thürlimann B, Robertson JF, Nabholtz JM, et al: Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 39:2310-2317, 2003 (Pubitemid 37214855)
    • (2003) European Journal of Cancer , vol.39 , Issue.16 , pp. 2310-2317
    • Thurlimann, B.1    Robertson, J.F.R.2    Nabholtz, J.M.3    Buzdar, A.4    Bonneterre, J.5
  • 5
    • 38349098666 scopus 로고    scopus 로고
    • Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer
    • Rossi E, Morabito A, De Maio E, et al: Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer. J Clin Oncol 26:264-270, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 264-270
    • Rossi, E.1    Morabito, A.2    De Maio, E.3
  • 6
    • 1542359096 scopus 로고    scopus 로고
    • Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
    • DOI 10.1038/sj.bjc.6601557
    • Forward DP, Cheung KL, Jackson L, et al: Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90:590-594, 2004 (Pubitemid 38297195)
    • (2004) British Journal of Cancer , vol.90 , Issue.3 , pp. 590-594
    • Forward, D.P.1    Cheung, K.L.2    Jackson, L.3    Robertson, J.F.R.4
  • 7
    • 60549097419 scopus 로고    scopus 로고
    • Endocrine therapy plus zoledronic acid in premenopausal breast cancer
    • Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
    • (2009) N Engl J Med , vol.360 , pp. 679-691
    • Gnant, M.1    Mlineritsch, B.2    Schippinger, W.3
  • 8
    • 67349280302 scopus 로고    scopus 로고
    • Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer
    • Han HS, Ro J, Lee KS, et al: Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat 115:335-342, 2009
    • (2009) Breast Cancer Res Treat , vol.115 , pp. 335-342
    • Han, H.S.1    Ro, J.2    Lee, K.S.3
  • 9
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors
    • European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
    • Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 14
    • 0028951579 scopus 로고
    • A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in preand perimenopausal patients with advanced breast cancer
    • Jonat W, Kaufmann M, Blamey RW, et al: A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in preand perimenopausal patients with advanced breast cancer. Eur J Cancer 31A:137-142, 1995
    • (1995) Eur J Cancer , vol.31 A , pp. 137-142
    • Jonat, W.1    Kaufmann, M.2    Blamey, R.W.3
  • 16
    • 0037157603 scopus 로고    scopus 로고
    • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial
    • DOI 10.1016/S0140-6736(02)09088-8
    • Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002 (Pubitemid 34694019)
    • (2002) Lancet , vol.359 , Issue.9324 , pp. 2131-2139
    • Baum, M.1    Buzdar, A.U.2    Cuzick, J.3    Forbes, J.4    Houghton, J.5    Klijn, J.G.M.6    Sahmoud, T.7
  • 17
    • 49949115926 scopus 로고    scopus 로고
    • Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-Year follow-up of the ABCSG-12 bone-mineral density substudy
    • Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al: Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-Year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840-849, 2008
    • (2008) Lancet Oncol , vol.9 , pp. 840-849
    • Gnant, M.1    Mlineritsch, B.2    Luschin-Ebengreuth, G.3
  • 19
  • 20
    • 38549180762 scopus 로고    scopus 로고
    • Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer
    • suppl 8
    • Perez EA: Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 18:viii26-viii35, 2007 (suppl 8)
    • (2007) Ann Oncol , vol.18
    • Perez, E.A.1
  • 21
    • 54849424382 scopus 로고    scopus 로고
    • Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer
    • Yamamoto Y, Iwase H: Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer. Int J Clin Oncol 13:384-394, 2008
    • (2008) Int J Clin Oncol , vol.13 , pp. 384-394
    • Yamamoto, Y.1    Iwase, H.2
  • 22
    • 79951789895 scopus 로고    scopus 로고
    • Minister for Health, Welfare, and Family Affairs, National Cancer Center: Goyang-si
    • Minister for Health, Welfare, and Family Affairs, National Cancer Center: Cancer Facts & Figures 2009 in the Republic of Korea. Goyang-si, 2009
    • (2009) Cancer Facts & Figures 2009 in the Republic of Korea
  • 23
    • 58549110458 scopus 로고    scopus 로고
    • Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone
    • Jannuzzo MG, Di Salle E, Spinelli R, et al: Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast Cancer Res Treat 113:491-499, 2009
    • (2009) Breast Cancer Res Treat , vol.113 , pp. 491-499
    • Jannuzzo, M.G.1    Di Salle, E.2    Spinelli, R.3
  • 24
  • 26
    • 45749089797 scopus 로고    scopus 로고
    • Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole
    • DOI 10.1634/theoncologist.2007-0206
    • Brufsky A, Bundred N, Coleman R, et al: Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13:503-514, 2008 (Pubitemid 351872868)
    • (2008) Oncologist , vol.13 , Issue.5 , pp. 503-514
    • Brufsky, A.1    Bundred, N.2    Coleman, R.3    Lambert-Falls, R.4    Mena, R.5    Hadji, P.6    Jin, L.7    Schenk, N.8    Ericson, S.9    Perez, E.A.10
  • 27
    • 67649804881 scopus 로고    scopus 로고
    • Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results
    • Brufsky AM, Bosserman LD, Caradonna RR, et al: Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77-85, 2009
    • (2009) Clin Breast Cancer , vol.9 , pp. 77-85
    • Brufsky, A.M.1    Bosserman, L.D.2    Caradonna, R.R.3
  • 28
    • 0035312469 scopus 로고    scopus 로고
    • Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases
    • Berenson JR, Rosen LS, Howell A, et al: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91:1191-1200, 2001
    • (2001) Cancer , vol.91 , pp. 1191-1200
    • Berenson, J.R.1    Rosen, L.S.2    Howell, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.